A reshuffle at Daiichi Sankyo and appointments at Fate Therapeutics and 3-V Biosciences – People on the move
Daiichi Sankyo has proposed that Joji Nakayama take the positions of president and CEO. Current CEO Takashi Shoda is due to take the role of chairman, with Kiyoshi Morita in-line to become corporate advisor.
Also, Nakayama, Kazunori Hirokawa, Hiroshi Hirabayashi, Ikuo Ishihara and Yuichiro Anzai have been selected as prospective board candidates.
Lee Rauch has been appointed as CEO of Nuon Therapeutics. Rauch has previously worked at Point Biomedical, Onyx, COR Therapeutics and Syntex.
Fate Therapeutics has named Tom Novak as vice president (VP) of research and drug discovery. Novak most recently worked at Roche and has also held positions at Wyeth.
Stephen Brady has been hired as VP, corporate development, strategy and operations at 3-V Biosciences. Earlier in his career Brady worked at Proteolix, Lexicon Pharmaceuticals and Lazard Venture Advisors.
3-V has also promoted to Robert McDowell to the position of VP, research. McDowell joined 3-V in 2008 and has also worked at Sunesis, Genentech and Axys Pharmaceuticals.
Mikel Moyer has been named as VP of molecular discovery at Epizyme. Moyer joins from the Broad Institute and also worked at Pfizer for 18 years.
Cobalis has appointed Martin Marion as CEO. Marion has previously worked at Grey Advertising / Grey Direct and Medicus.
